RU2020115868A - РЕКОМБИНАНТНАЯ ЭКСПРЕССИЯ БЕЛКА ORF2 PCV2b В КЛЕТКАХ НАСЕКОМЫХ - Google Patents
РЕКОМБИНАНТНАЯ ЭКСПРЕССИЯ БЕЛКА ORF2 PCV2b В КЛЕТКАХ НАСЕКОМЫХ Download PDFInfo
- Publication number
- RU2020115868A RU2020115868A RU2020115868A RU2020115868A RU2020115868A RU 2020115868 A RU2020115868 A RU 2020115868A RU 2020115868 A RU2020115868 A RU 2020115868A RU 2020115868 A RU2020115868 A RU 2020115868A RU 2020115868 A RU2020115868 A RU 2020115868A
- Authority
- RU
- Russia
- Prior art keywords
- protein
- pcv2b
- mutant
- orf2
- proline
- Prior art date
Links
- 241000238631 Hexapoda Species 0.000 title claims 8
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 title claims 8
- 101710130262 Probable Vpr-like protein Proteins 0.000 title claims 8
- 108090000623 proteins and genes Proteins 0.000 title claims 4
- 102000004169 proteins and genes Human genes 0.000 title claims 4
- 238000003259 recombinant expression Methods 0.000 title 1
- 229960005486 vaccine Drugs 0.000 claims 8
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 claims 7
- 101710113540 ORF2 protein Proteins 0.000 claims 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 7
- 101710090523 Putative movement protein Proteins 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 241001673669 Porcine circovirus 2 Species 0.000 claims 5
- 102000008300 Mutant Proteins Human genes 0.000 claims 4
- 108010021466 Mutant Proteins Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 241000282887 Suidae Species 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 241000701447 unidentified baculovirus Species 0.000 claims 2
- 108700040077 Baculovirus p10 Proteins 0.000 claims 1
- 108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Claims (20)
1. Клетки насекомых, содержащие гетерологичную нуклеиновую кислоту, включающую:
a. нуклеотидную последовательность, кодирующую белок ORF2 цирковируса 2 свиней с генотипом 2b (PCV2b), и
b. контролирующую транскрипцию последовательность, которая функционально связана с указанной нуклеотидной последовательностью, отличающиеся тем, что нуклеотидная последовательность кодирует мутантный белок ORF2 PCV2b, имеющий пролин в аминокислотном положении 131.
2. Клетки насекомых по п.1, отличающиеся тем, что контролирующая транскрипцию последовательность представляет собой промотор гена р10 бакуловируса или промотор гена полиэдрина бакуловируса.
3. Клетки насекомых по п.1 или 2, отличающиеся тем, что гетерологичная нуклеиновая кислота содержится в геноме рекомбинантного бакуловируса.
4. Вирусоподобные частицы (VLP) мутантного белка ORF2 PCV2b, отличающиеся тем, что мутантный белок ORF2 PCV2b имеет пролин в аминокислотном положении 131.
5. Способ экспрессии мутантного белка ORF2 PCV2b в клетках насекомых по любому из пп. 1-3, в котором используется бакуловирусная система экспрессии в клетках насекомых.
6. Способ получения мутантного белка ORF2 PCV2b, имеющего пролин в аминокислотном положении 131, причем получение включает одну или обе стадии, выбранные из:
культивирования клеток насекомых по любому из пп. 1-3; и
сбора мутантного белка ORF2 PCV2b из культуры клеток насекомых.
7. Вакцина для свиней для подавления PCV2 инфекции или связанных с ней признаков заболевания, содержащая мутантный белок ORF2 PCV2b в фармацевтически приемлемом носителе, отличающаяся тем, что указанный мутантный белок ORF2 PCV2b имеет пролин в аминокислотном положении 131.
8. Вакцина по п.7, отличающаяся тем, что мутантный белок ORF2 PCV2b находится в форме VLP.
9. Вакцина по п.7 или 8, содержащая адъювант.
10. Вакцина по любому из пп. 7-9, содержащая дополнительный антиген микроорганизма, патогенного для свиней.
11. Способ подавления PCV2 инфекции или связанных с ней признаков заболевания у свиньи, включающий введение указанной свинье вакцины по любому из пп. 7-10.
12. Применение мутантного белка ORF2 PCV2b, имеющего пролин в аминокислотном положении 131, для получения вакцины для свиней для подавления PCV2 инфекции или связанных с ней признаков заболевания.
13. Мутантный белок ORF2 PCV2b, имеющий пролин в аминокислотном положении 131, для применения в вакцине для свиней для подавления PCV2 инфекции или связанных с ней признаков заболевания.
14. Способ получения вакцины по любому из пп. 7-10, включающий одну или более стадий, выбранных из:
смешивания мутантного белка ORF2 PCV2b, имеющего пролин в аминокислотном положении под номером 131, с фармацевтически приемлемым носителем; и
составления указанной смеси мутантного белка ORF2 PCV2b и фармацевтически приемлемого носителя вместе с адъювантом.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17196768 | 2017-10-17 | ||
| EP17196768.0 | 2017-10-17 | ||
| PCT/EP2018/078189 WO2019076864A1 (en) | 2017-10-17 | 2018-10-16 | RECOMBINANT EXPRESSION OF PCV2B ORF2 PROTEIN IN INSECT CELLS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2020115868A true RU2020115868A (ru) | 2021-11-18 |
| RU2020115868A3 RU2020115868A3 (ru) | 2021-11-18 |
| RU2779423C2 RU2779423C2 (ru) | 2022-09-06 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200066700A (ko) | 2020-06-10 |
| CN111212847A (zh) | 2020-05-29 |
| JP2022065059A (ja) | 2022-04-26 |
| DK3697804T3 (da) | 2023-11-13 |
| JP7062760B2 (ja) | 2022-05-06 |
| PL3697804T3 (pl) | 2024-01-03 |
| MX2020003626A (es) | 2021-08-12 |
| US11279952B2 (en) | 2022-03-22 |
| CA3078281C (en) | 2023-02-21 |
| BR112020007498A2 (pt) | 2020-10-06 |
| JP2020537651A (ja) | 2020-12-24 |
| CA3078281A1 (en) | 2019-04-25 |
| ES2962449T3 (es) | 2024-03-19 |
| JP7422795B2 (ja) | 2024-01-26 |
| KR102480771B1 (ko) | 2022-12-23 |
| US20200299726A1 (en) | 2020-09-24 |
| CN111212847B (zh) | 2024-01-30 |
| EP3697804A1 (en) | 2020-08-26 |
| WO2019076864A1 (en) | 2019-04-25 |
| RU2020115868A3 (ru) | 2021-11-18 |
| EP3697804B1 (en) | 2023-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101610786B (zh) | 预防和治疗亚临床pcvd | |
| Mena et al. | Insect cell technology is a versatile and robust vaccine manufacturing platform | |
| JP5890469B2 (ja) | 高病原性ブタ繁殖・呼吸障害症候群（ｈｐｐｒｒｓ）のワクチン | |
| US7914992B2 (en) | Treatment of PRDC in pigs | |
| Feng et al. | Canine parvovirus VP2 protein expressed in silkworm pupae self-assembles into virus-like particles with high immunogenicity | |
| Bucarey et al. | The optimized capsid gene of porcine circovirus type 2 expressed in yeast forms virus-like particles and elicits antibody responses in mice fed with recombinant yeast extracts | |
| CN106399350B (zh) | 一种猪圆环病毒ii型病毒样颗粒疫苗及其制备方法 | |
| CN108456663B (zh) | 一种1型牛病毒性腹泻病毒样颗粒及其制备与应用 | |
| Duan et al. | Efficient production of porcine circovirus virus-like particles using the nonconventional yeast Kluyveromyces marxianus | |
| JP7422795B2 (ja) | 昆虫細胞でのＰＣＶ２ｂ ＯＲＦ２タンパク質の組換え発現 | |
| EP2154149B1 (en) | A truncated l1 protein of human papillomavirus 6 | |
| US20230302113A1 (en) | Porcine Circovirus Type 3 (PCV3) Vaccines, and Production and Uses Thereof | |
| CN1730101A (zh) | O型口蹄疫病毒多基因复制缺陷型腺病毒活载体疫苗及制备方法 | |
| Ignacio Casal | Use of the baculovirus expression system for the generation of virus-like particles | |
| Jeoung et al. | Immune responses and expression of the virus-like particle antigen of the porcine encephalomyocarditis virus | |
| CN103059142B (zh) | 猪圆环病毒的抗原和猪繁殖与呼吸综合征病毒的抗原的重组蛋白及其制备方法与应用 | |
| Dong et al. | Immune responses of mice immunized by DNA plasmids encoding PCV2 ORF 2 gene, porcine IL-15 or the both | |
| CN113896773B (zh) | 重组fcv抗原及猫嵌杯病毒基因工程亚单位疫苗 | |
| Li et al. | Development and characterization of Rift Valley fever virus-like particles | |
| WO2013030608A1 (en) | Nanoparticle-based veterinary vaccine | |
| KR102568329B1 (ko) | 조류인플루엔자 뉴라미니다아제를 포함하는 바이러스-유사입자 및 이를 이용한 범용 백신 | |
| RU2546240C1 (ru) | РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 56 | |
| KR102477253B1 (ko) | 강화된 조류 인플루엔자 바이러스-유사입자를 포함하는 백신 조성물 및 이의 제조 방법 | |
| Wang et al. | Comparison of immune effects of porcine circovirus type 2d (PCV2d) capsid protein expressed by Escherichia coli and baculovirus-insect cells | |
| JP2023549461A (ja) | バキュロウイルス発現ベクター |